Anixa Biosciences, Inc.
NASDAQ•ANIX
CEO: Dr. Amit Kumar Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 1983-10-07
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
連絡先情報
時価総額
$96.47M
PER (TTM)
-8.6
17.8
配当利回り
--
52週高値
$5.46
52週安値
$2.33
52週レンジ
順位52Top 73.5%
2.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$0.00+0.00%
直近4四半期の推移
EPS
-$0.08-127.20%
直近4四半期の推移
フリーCF
-$1.26M+35.38%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Breast Vaccine Phase 1 Data Breast cancer vaccine Phase 1 completed; 74% subjects met protocol defined immune endpoints; preparing Phase 2 study.
CAR-T Trial Advancement Ovarian cancer lira-cel Phase 1 dose escalation complete; treatment well-tolerated across cohorts; study completion estimated 2-3 years.
R&D Spending Reduced Total R&D expenses decreased 20.6% to $5.071M in FY2025 from $6.396M in FY2024, driven by vaccine timing.
Cash Runway Secured Cash, equivalents, and investments total $15.174M as of October 31, 2025; sufficient to fund activities for next twelve months.
リスク要因
History of Losses Continues History of substantial losses; requires future capital raises potentially resulting in significant stockholder dilution and reduced liquidity.
Early Stage Development Risks Therapeutics and vaccines are pre-revenue; development faces uncertainties, reliance on third parties, and potential failure to reach market.
Intense Competitive Landscape Competitors possess greater financial, technical resources; may achieve market acceptance faster, rendering proprietary products obsolete.
Reliance on Key Licenses Business relies heavily on licenses from Wistar and Cleveland Clinic; loss of these rights severely limits development capability.
見通し
Primary Focus on Development Expect development of therapeutics and vaccines to remain the primary focus over the next several quarters for the Company.
Future Licensing Strategy Hopes to achieve profitability by eventually licensing technologies to large pharmaceutical companies for manufacturing and sales.
Expanding Vaccine Pipeline Joint agreement established to discover additional vaccine targets for high incidence cancers like lung, colon, and prostate.
No Near-Term Dividends Current policy retains all earnings for operation and expansion; no cash dividends are planned in the foreseeable future.
同業比較
売上高 (TTM)
$106.83M
$35.95M
$35.77M
粗利益率 (最新四半期)
100.0%
99.6%
83.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CYBN | $413.02M | -1.8 | -61.5% | 15.9% |
| GLSI | $341.79M | -17.3 | -1042.8% | 0.0% |
| IRD | $328.96M | -4.9 | -774.2% | 3.0% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年3月9日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし